Navigation Links
China Shenghuo Reports Full Year 2007 Financial Results
Date:4/1/2008

INC.

AUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

For the Years Ended

December 31,

2007 2006

Supplemental Information

Cash paid for interest $ 781,030 $ 757,432

Cash paid for income taxes 98,357 --

Noncash investing and financing

activities

Reduction in carrying amount of

assets related to acquisition

of minority interest $ -- $ 440,158

Conversion of common shares to

minority interest -- 223,312

For more information, please contact:

China Shenghuo Pharmaceutical Holdings, Inc.

Ms. Gao Qionghua, CFO

Tel: +86-871-7282608

Email: qionghua_kmsh@163.com

CCG Elite Investor Relations

Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
2. China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour
3. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
4. China Yingxia International Announces Soybean Milk Production Lines Acquisition
5. Cells from the Research Institute of the MUHC on the road to China
6. China Medicine Announces Record Fourth Quarter and Fiscal Year 2007 Results
7. China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
8. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
9. China RuiTai International Holdings Retains CCG Elite for Investor Relations Services
10. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
11. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ute asthma attacks be causing the very thing it ai...ard School of Public Health and Brigham and Women’...known as beta-agonists in asthmatics. Beta-agonist... used to relieve acute asthma attacks. The drugs c...
... do prevent the onset of Parkinson’s disease. The ...o regularly take nonsteroidal// anti-inflammatory ...n those who did not take the drugs. Parkinson’s di... neurons in the brain. The result is a loss in mot...
...researchers say mindful meditation can have a posi...t the University of //Wisconsin, determined the pr...side of the brain and has a healthy effect. The re...rk environment with healthy employees. During an e...
...killers during pregnancy increases the risk of mis...hich include// aspirin and ibuprofen, are some of ...regnant women. Doctors interviewed 1,055 pregnant ...heir pregnancy. The participants were asked questi...
Other Medicine News:
(Date:10/6/2008)...ore than 60 percent of moderate to severe patients...cent achieved endoscopic remission at Week 10,in d...he American College,of Gastroenterology (ACG) Annu...ewswire/ -- UCB today presented data from a,large,...ement in Crohn,s,disease (CD) with a biologic comp...
(Date:10/6/2008)...EATTLE, Oct. 6 /- Dendreon ...call today, Monday, October 6, 2008 at 9:00 AM,ET ...analysis of its IMPACT,(IMmunotherapy for Prostate...linical trial of PROVENGE(R) (sipuleucel-T), the C...rapy for the treatment of advanced prostate,cancer...
(Date:10/3/2008)...urlington County, New Jersey is the newest study s... -- The Children,s Hospital,of Philadelphia today ...The,National Children,s Study. Children,s Hospital...data collection in Burlington County, New,Jersey. ...Health., Investigators anticipate approximately 1...
(Date:10/2/2008)...udy to support Urgent PC clinical success and expa...coverage, MINNEAPOLIS, Oct. 2 /PRNewswire-FirstCa... the enrollment of the first patients in a new,ran...its FDA cleared Urgent,PC neuromodulation system f...oms of urinary urgency, urge incontinence and freq...
Breaking Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 3Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 4 CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement 3A Australia New Z 7377 1 CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement 3A Australia New Z 7377 2Ortho McNeil Neurologics to Appeal Patent Ruling on RAZADYNE 28R 29 7373 1Ortho McNeil Neurologics to Appeal Patent Ruling on RAZADYNE 28R 29 7373 2Ortho McNeil Neurologics to Appeal Patent Ruling on RAZADYNE 28R 29 7373 3Medivation Announces Participation in Upcoming Conferences 7371 1Medivation Announces Participation in Upcoming Conferences 7371 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL 28R 29 D Dimer Assay 7367 1Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL 28R 29 D Dimer Assay 7367 2
...ted against CTCL, PTCL and Ovarian Cancers,-, BRAN...-- CuraGen,Corporation , a clinical-stage biopharm...oday an update on the clinical development,program...bitor, and,reported updated results suggesting cli...ell lymphoma (CTCL), peripheral T-cell,lymphoma (P...
...SS WIRE)--Jun 12, 2007 - Critical,Therapeutics, In...of data from a pivotal Phase III clinical trial of...in the June 2007 issue of the,Journal of Asthma. Z...inistration (FDA) on May 30, 2007. Critical Therap..., L.P. (DEY), expects to,begin marketing ZYFLO CR ...
Other Medicine Technology:CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
Features soft, low friction sheath that extends beyond the tip.
Designed to retain the desired curve during oral intubation.
Facilitates intubation of tracheal tubes.
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box.
Medicine Products: